Persistence of antibodies acquired by natural hepatitis E virus infection and effects of vaccination

Naturally acquired anti–hepatitis E virus (HEV) immunity can protect against new HEV infections. The aim of this study was to analyse the persistence of naturally acquired anti-HEV immunoglobulin (Ig) G and anti-HEV IgG concentrations after vaccination. We examined the seropositivity rates of partic...

Full description

Saved in:
Bibliographic Details
Published in:Clinical microbiology and infection 2017-05, Vol.23 (5), p.336.e1-336.e4
Main Authors: Su, Y.-Y., Huang, S.-J., Guo, M., Zhao, J., Yu, H., He, W.-G., Jiang, H.-M., Wang, Y.-J., Zhang, X.-F., Cai, J.-P., Yang, C.-L., Wang, Z.-Z., Zhu, F.-C., Wu, T., Zhang, J., Xia, N.-S.
Format: Article
Language:English
Subjects:
Antibody level
Case-Control Studies
Dose-Response Relationship, Immunologic
Follow-Up Studies
Hepatitis Antibodies - blood
Hepatitis E - immunology
Hepatitis E virus
Humans
Immunoglobulin G - blood
Mathematical model
Persistence
Vaccination
Vaccine
Vaccines, Synthetic - administration & dosage
Vaccines, Synthetic - therapeutic use
Viral Hepatitis Vaccines - administration & dosage
Viral Hepatitis Vaccines - therapeutic use
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Naturally acquired anti–hepatitis E virus (HEV) immunity can protect against new HEV infections. The aim of this study was to analyse the persistence of naturally acquired anti-HEV immunoglobulin (Ig) G and anti-HEV IgG concentrations after vaccination. We examined the seropositivity rates of participants included in a phase 3 clinical efficacy trial (67 months' follow-up) for a HEV vaccine (Hecolin; Xiamen Innovax Biotech, China) and predicted long-term persistence using mixed-effect models. The analysis focused on 2242 baseline seropositive participants in a control group (placebo recipients) and 2031 baseline seropositive participants in an vaccine group (vaccine recipients) who received 1 to 3 doses of Hecolin. Naturally acquired anti-HEV IgG levels decreased steadily independent of the initial antibody level; 50% of the placebo recipients were expected to have undetectable antibody concentrations after 14.5 years. After immunization with Hecolin, the power-law model and the modified power-law model predicted that 82.1 and 99.4% of the participants, respectively, would remain seropositive for anti-HEV IgG for 30 years after vaccination. Whereas naturally acquired anti-HEV IgG levels decrease steadily, HEV vaccination induces long-lasting, high-level anti-HEV IgG concentrations.
ISSN:1198-743X
1469-0691
DOI:10.1016/j.cmi.2016.10.029